Victoria Socha
Articles by Victoria Socha
NOBLE examined the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3G or IC-MPGN.
A study examined the effects of adding dapagliflozin to treatment with tolvaptan in patients with ADPKD.
Previous studies suggest a link between CKD and sleep disorders, but the nature of the association is unclear.
A study examined the safety and noninferiority of kidney transplantation from donors with HIV to recipients with HIV.
A systematic review and meta-analysis evaluated the safety of statin use among kidney allograft recipients.
Does the prevalence of cardiovascular-kidney-metabolic syndrome stages vary by social determinants of health?
Is time to death from withdrawal of life-sustaining treatment is associated with kidney transplant outcomes?
The TRANSNEMIA study addressed the need for guidelines specific to anemia in kidney transplant recipients.
Researchers studied variation in AKI incidence with IV antihypertensive treatment after severe hypertension.
A study examined the efficacy and safety of conversion from treatment with the long-acting ESA MPG-EPO to vadadustat.
A global review noted changes in kidney care delivery but revealed gaps in access to kidney replacement therapies.
A study examined the impact of hemodiafiltration versus hemodialysis in patients with end-stage renal disease.
CERTAIN registry data were used to assess age-related differences in outcomes among pediatric kidney transplant recipients.
Researchers studied the clinical relevance of allograft microvascular inflammation in kidney transplantation.
Development of a transplant morbidity gene panel highlights how genetic testing could open the door to personalized care.
Researchers studied outcomes of transplant recipients who received kidneys from toxoplasma-positive versus negative donors.
A study examined an association between hyperglycemic crises at diabetes diagnosis and a higher risk of developing CKD.
Researchers evaluated efficacy and safety of allopurinol versus febuxostat for gout in patients with stage 3 CKD.
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.